Abraaj Group invests in Uganda pharmacy chain
Nairobi, January 30, 2013
The Abraaj Group, a leading private equity investor operating in global growth markets, today announced an investment by its Africa Health Fund in Vine Pharmaceuticals, the largest pharmacy retail chain in Uganda.
The investment is the Africa Health Fund’s first in the pharmaceutical retail and distribution sector, said a statement.
It will help Vine to expand its reach and market share in Uganda’s rapidly growing pharmaceutical market, where expenditure is growing at a CAGR of 13 per cent and forecast to increase from the $268 million spent in 2011 to $545 million by 2014.
The Africa Health Fund was established in June 2009 with the International Finance Corporation, The African Development Bank, DEG, and the Bill & Melinda Gates Foundation as cornerstone investors. The Fund’s unique objective is to improve the access of low-income Africans to affordable, high quality health services while providing investors with strong long-term financial returns.
Shakir Merali, Partner, The Abraaj Group, said: "Vine will be an important beneficiary of the continued growth in pharmaceutical expenditure in Uganda through both its retail and wholesale businesses.”
Grace Munyirwa, founder and director of Vine Pharmaceuticals, said: “I am proud of the work our team has done to take Vine to its leading position in the Ugandan market, and I am looking forward to taking the business to the next level with Abraaj’s support. Their expertise in the health sector and their track record of helping to grow businesses by investing in operational improvements and more sophisticated business management systems will make them the perfect partners as we expand our presence across the country and develop our promising wholesale business.”
The Abraaj Group is one of the leading private equity investors in the healthcare sector in growth markets around the world. Its Funds’ investments include stakes in the Philippines retail pharmacy chain HBC, and in Saudi Arabia’s Tadawi Group, both leaders in their local markets. Additionally, the Group has current investments in nine hospitals (following two recent successful healthcare exits in Asia), as well as in pharmaceuticals, diagnostics, and medical devices manufacturing.
The Abraaj Group operates in the global growth markets of Asia, Mena, Turkey and Central Asia, Sub-Saharan Africa and Latin America. Employing over 300 people, the group has 33 country offices spread across seven regional hubs in Bogota, Dubai, Istanbul, London, Mumbai, Nairobi and Singapore.
The Abraaj Group currently manages $7.5 billion across 25 sector and country-specific funds encompassing private equity (majority and significant minority investments with ticket sizes between $10 million and $100 million invested under a global mandate) and real estate (primarily yield-generating) investments. - TradeArabia News Service
Tags: Pharmacy |
More Health & Environment Stories
- NCDs ‘to cost GCC $36bn in 2013’
- Arabtec inks $1.2bn UAE hospital contract
- Infectious disease control ‘urgent need for GCC’
- New HIV cases fall as Bahrain's efforts pay off
- Conference to discuss emergency medicine
- UAE reports 3 more MERS cases
- Bahrain 'free of Mers coronavirus'
- 500,000 suffer from spinal cord injuries
- 3BL to assess Majaal corporate sustainability
- Diabetes experts to meet in Abu Dhabi